To determine whether growth hormone (GH) has any impact on the hyperlipidemia seen in cholestatic patients, graded doses of GH in the sequence of 0.1, 0.2, 0.4, and 0.6u/kg every other day were administered sc to a patient with Alagille syndrome.
that:GH has many effects on carbohydrate, protein and lipid metabolism (Konobil, 1966; Raiti and Blizzard, 1970; Merimee and Rabin 1973) . The reports dealing with the effect of GH on serum lipids are controversial (Friedman et al., 1970; Friedman et al., 1974; Aloia et al., 1975; Winter et al., 1979; Merimee and Pylkkinen, 1980; Blackett et al., 1982 ; Asayama et al., 1984) . Most of the above reports were limited to the subject of GH deficiency with only mild hypercholesterolemia, except for the study of Friedman et al.(1974) in which they found that daily administration of a very high pharmacologic dose of GH (25 u) to even normocholesterolemic and moderately hypercholesterolemic adults who had no reported GH deficiency caused a decrease in their serum cholesterol concentrations in one week. The effect of GH on the hyperlipidemia of cholestatic patients has not been studied, although such a study may help to find the exact effect of GH on serum lipid.
This report describes the effect of GH on hyperlipidemia in a boy with Alagille syndrome.
Materials
and Methods
Subject
An 8-year-old boy with Alagille syndrome was studied. His height was 109.2cm (-2.86 SD, height age 5 6/12yr) and his weight was 20.5kg. Bone age determined by the standards of Greulich and Pyle was 5 yr. Peak serum GH levels during an insulin-arginine tolerance test when he was 7 years old were 16 and 6.2ng/ ml, respectively. Serum SM-C was 0.38IU/ml. He has had chronic cholestasis since his neonatal period.
His liver function was disturbed after his birth but improved and remained stable after he was 6 years old. Although hyperbilirubinemia disappeared after infancy, serum total cholesterol and bile acid levels remained high. The yearly laboratory data since his birth are summarized in Figure 1 . His face is characteristic of the syndrome, with prominent forehead, moderate hypertelorism, deepset eyes, small chin, and Analytic methods Serum total cholesterol (Richmond, 1973) , bile acid (Mashige et al., 1981) , and phospholipid (Takayama et al., 1977) were all measured with commercial kits. SM-C was assayed with a double antibody RIA Kit (Eiken Immunochemical Laboratory, Tokyo, Japan).
FT3 was assayed with an Amerlex RIA Kit (Amersham International of PLC, Buckinghamshire, England).
Results
Laboratory data before, during and after the administration of various doses of hGH are summarized in Figure 2 . Total cholesterol, phospholipid, and bile acid decreased from 362mg/dl, 520mg/dl, and 72 pmol/L to 268mg/dl, 381mg/dl, and 10.6 pmol/L respectively, two days after the injection of a low dose (0.1u/kg) of hGH. Their lowest levels (214mg/dl, 274mg/dl, and 3.5 taneously one day after the third injection (0.4u/kg).
But thereafter rebounding increases were found with maximal levels of 256mg/dl, 392mg/dl, and 300 pmol/, respectively, two days after the fourth injection injection. Neither SM-C nor fT3 showed any changes correlated with total cholesterol, phospholipid, or bile acid.
Discussion
Previous studies dealing with the effect of GH on serum lipids are controversial (Friedman et al., 1970; Friedman et al., 1974; Aloia et al., 1975; Winter et al., 1979; Merimee and Pulkkinen et al., 1980; Blackett et al., 1982; Asayama et al., 1984) ; Treatment with GH lowered cholesterol concentrations in hypox rats (Friedman et al., 1970) and GH-deficient individuals in two studies (Blackett et al., 1982; Asayama et al., 1984) but had no effect in GH-deficient patients in two others (Winter et 1979; Merimee and Fulkkinen, 1980) . In normal individuals, GH caused a decrease in cholesterol after 1 week's administration of very large doses (Friedman et al., 1974) but not after 6 months' administration of lesser amounts (Aloia et al. 1975) . The effect of GH on the hyperlipidemia seen in cholestatic patients has not been studied.
Our results indicate that GH at a proper dose may lower not only the high level cholesterol but also the high levels of phospholipid and bile acid in cholestatic patients. The basic defect leading to cholestasis in Alagille syndrome is not well known. In spite of the absence or paucity of intrahepatic bile ducts, variable amounts of bile secreted into the intestinal lumen can be demonstrated in the majority of patients with Alagille syndrome; extrahepatic biliary ducts are usually patent, although they can be hypoplastic (Watson and Miller, 1973; Henriksen et al. 1977; Grosse, 1979; Gorelick et al., 1982; Kahn et al., 1983; Markowitz et al., 1983) . The intralobular bile is probably drained through a network of functional canaliculi to an area where bile ducts are patent. Patients with this syndrome have high levels of serum bilirubin and bile acid during infancy, but after that period bilirubin decreases to the normal level and the bile acid remains high (Riely et al., 1979) . The dissociation between bile acid and bilirubin may indicate that a disturbance in bile acid secretion is involved in this syndrome.
The precise mechanism of the dramatic decrease in serum bile acid after hGH administrations as found in this patient, although not clear, may be due to the enhancing effect of GH on bile acid secretion from canaliculi. Since the changes in serum levels of total choresterol and phospholipid were almost concomitant with the change in the serum bile acid level, the decreases in both may be due to the excretion of both from bile acid (Grundy and Metzger, 1972) . But to confirm this, a study of the influence of GH on gallbladder bile composition, bile (concentration of cholesterol, bile acids, and phospholipids) would be necessary.
The rebounding increases in total cholesterol, phospholipid, and especially bile acids after large doses of hGH (0.4 and 0.6u/kg) may be explained by the feed-back secretion of somatostatin, since somatostatin has a cholestatic effect on bile secretion by enhancing ductal or canalicular bile reabsorption (Holm et al. 1978; Meyer et al., 1979; Ricci and Fevery, 1981; Rene et al., 1983) .
Subclinical hypothyroidism developing during GH therapy may be related to the mild hypercholesterolemia seen in some GH-deficient subjects (Goodman et al., 1968; Porter et al., 1973) suggesting that thyroid hormone may have an effect on cholesterol metabolism.
The administration of hGH did not change the concentration of fT3 in this patient, indicating that the reduction in serum cholesterol that was observed could not have been due to thyroid hormone. Changes in serum SM-C were not correlated with the changes in total cholesterol, phospholipid, and bile acid, suggesting that the three may not be related to SM-C.
